Baitao Zhang1, Jiangqiao Geng, Fang Nie, Xiaoming Li. 1. Department of Otolaryngology-Head and Neck Surgery, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, China.
Abstract
BACKGROUND: The purpose of this study was to determine whether the pretreatment primary tumor standardized uptake value (SUV), as measured by positron emission tomography (PET), can add prognostic information for predicting survival in patients with head and neck squamous cell carcinoma (HNSCC). MATERIALS AND METHODS: 7 articles were identified by searching electronic databases. Statistical analysis was performed with RevMan 4.2.2. SUV measurement and SUV threshold for defining high SUV were studied dependently. For each publication, we first obtained an estimate of the relative risk (RR) for comparing patients with a low or a high SUV. Subsequently, we aggregated the individual RRs into a combined RR, using a fixed-effect model. Publication bias was assessed using a funnel plot. RESULTS: The study included 7 clinical trials dedicated to HNSCC, involving 674 patients who underwent fluoro-2-deoxy-D-glucose-PET scanning before treatment. The combined RR from the 7 reports for the survival was 0.53 (95% confidence interval: 0.46-0.62). The funnel plot showed symmetrical distribution, indicating no evidence of any substantial publication bias. CONCLUSION: Our meta-analysis indicates that patients with HNSCC who have a primary tumor with a high SUV have poor survival; this should be further confirmed in a meta-analysis based on individual patient data.
BACKGROUND: The purpose of this study was to determine whether the pretreatment primary tumor standardized uptake value (SUV), as measured by positron emission tomography (PET), can add prognostic information for predicting survival in patients with head and neck squamous cell carcinoma (HNSCC). MATERIALS AND METHODS: 7 articles were identified by searching electronic databases. Statistical analysis was performed with RevMan 4.2.2. SUV measurement and SUV threshold for defining high SUV were studied dependently. For each publication, we first obtained an estimate of the relative risk (RR) for comparing patients with a low or a high SUV. Subsequently, we aggregated the individual RRs into a combined RR, using a fixed-effect model. Publication bias was assessed using a funnel plot. RESULTS: The study included 7 clinical trials dedicated to HNSCC, involving 674 patients who underwent fluoro-2-deoxy-D-glucose-PET scanning before treatment. The combined RR from the 7 reports for the survival was 0.53 (95% confidence interval: 0.46-0.62). The funnel plot showed symmetrical distribution, indicating no evidence of any substantial publication bias. CONCLUSION: Our meta-analysis indicates that patients with HNSCC who have a primary tumor with a high SUV have poor survival; this should be further confirmed in a meta-analysis based on individual patient data.
Authors: Lorenzo Preda; Giorgio Conte; Luke Bonello; Caterina Giannitto; Laura L Travaini; Sara Raimondi; Paul E Summers; Ansarin Mohssen; Daniela Alterio; Maria Cossu Rocca; Chiara Grana; Francesca Ruju; Massimo Bellomi Journal: Eur Radiol Date: 2016-03-10 Impact factor: 5.315
Authors: Kondaveeti Satish Srinivas; M Arunan; E Venkatachalapathy; Christopher John; M Manickavasagam; C V Divyambika Journal: J Int Soc Prev Community Dent Date: 2019-04-12
Authors: Steve Connor; Cherry Sit; Mustafa Anjari; Teresa Szyszko; Joel Dunn; Irumee Pai; Gary Cook; Vicky Goh Journal: Cancer Rep (Hoboken) Date: 2021-05-07